Key points are not available for this paper at this time.
To the editor: Treatment with the Janus-activated kinase (JAK) 1 and 2 inhibitor ruxolitinib decreases constitutional symptoms and spleen size in myelofibrosis. However, accumulating evidence suggests that the drug also exerts substantial immunosuppressive activity.11,22 A very recent
Heine et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: